Monroe Research, LLC

West Monroe, Louisiana 71291

8 studies enrolling now · 14 studies all time

What they study most

Acute Coronary Syndrome, Atherosclerotic Cardiovascular Disease, Atrial Fibrillation (AF), Cardiovascular Disease, Cardiovascular Diseases, Chronic Heart Failure, Diabetes Mellitus, Type 2, Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease, Hypercholesterolaemia, Hypertension, Lipoprotein Disorder, Percutaneous Coronary Intervention

Studies at this site

• OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events — Recruiting now
• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Recruiting now
• Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention — Recruiting now
• Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation — Recruiting now
• Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease — Recruiting now
• A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia — Recruiting now
• Pelacarsen Roll-over Extension Program — Recruiting now
• Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable — Recruiting now
• A Study of DII235 in Adults With Elevated Lipoprotein(a) — Running, not enrolling
• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. — Running, not enrolling
• A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome — Completed
• Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction — Completed
• Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD — Completed
• Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial — Running, not enrolling